PRGO PERRIGO Co plc
Pharmaceutical Preparations · NYSE · SEC CIK 1585364 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.5%
TTM net income YoY-3,316.4%
TTM EPS YoY-3,351.4%
Revenue 3-yr CAGR-4.2%
Net income 3-yr CAGR—
Margins
Gross margin32.3%
Operating margin-39.4%
Net margin-43.3%
FCF margin4.1%
EBITDA margin-33.6%
Returns
ROE-51.4%
ROA-20.1%
ROIC (approx.)-19.7%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets67.4%
Debt / equity1.35x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-26 | 2026Q22026-06-27 | 2026Q12026-03-28 | 2025Q4*2025-12-31 | 2025Q32025-09-27 | 2025Q22025-06-28 | 2025Q12025-03-29 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $988.60M | $1.02B | $969.20M | $1.11B | $1.04B | $1.06B | $1.04B | $1.14B |
| Cost of revenue | $667.80M | $708.90M | $643.70M | $747.40M | $666.20M | $693.40M | $651.60M | $752.40M |
| Gross profit | $320.80M | $313.90M | $325.50M | $362.20M | $377.10M | $362.90M | $392.30M | $385.90M |
| R&D expense | $21.90M | $23.70M | $24.60M | $21.80M | $24.90M | $22.00M | $26.70M | $27.80M |
| SG&A expense | $124.50M | $100.00M | $115.00M | $116.50M | $94.20M | $113.00M | $112.20M | $94.70M |
| Operating income | $23.10M | $23.50M | -$372.30M | -$1.29B | $72.60M | $45.40M | $46.90M | $114.20M |
| Pretax income | -$18.10M | $105.40M | -$408.50M | -$1.33B | $22.40M | $3.20M | $8.30M | $70.00M |
| Income tax | -$3.80M | $16.90M | -$18.70M | $82.90M | $9.70M | $3.70M | $8.20M | $111.50M |
| Net income | -$27.50M | $74.50M | -$398.60M | -$1.42B | $7.50M | -$8.40M | -$6.40M | -$44.50M |
| EBITDA | $50.60M | $64.90M | -$289.00M | -$1.20B | $102.00M | $74.70M | $126.80M | $194.50M |
| EPS (basic) | -0.20 | 0.54 | -2.87 | — | 0.05 | -0.06 | -0.05 | — |
| EPS (diluted) | -0.20 | 0.53 | -2.87 | — | 0.05 | -0.06 | -0.05 | — |
| Dividends declared per share | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 |
| Weighted avg. shares (diluted) | 139.40M | 139.60M | 138.70M | — | 138.90M | 138.20M | 137.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $436.60M | $399.70M | $357.20M | $531.60M | $432.10M | $454.20M | $409.90M | $558.80M |
| Receivables | $685.50M | $709.90M | $697.10M | $612.80M | $644.40M | $678.20M | $716.80M | $642.30M |
| Inventory | $1.01B | $1.06B | $1.12B | $1.15B | $1.23B | $1.22B | $1.16B | $1.08B |
| Current assets | $2.40B | $2.45B | $2.71B | $2.80B | $2.88B | $2.62B | $2.53B | $2.48B |
| PP&E, net | $825.10M | $849.00M | $877.70M | $898.70M | $902.80M | $913.90M | $913.20M | $917.80M |
| Goodwill | $1.69B | $1.69B | $1.70B | $2.05B | $3.36B | $3.48B | $3.38B | $3.32B |
| Intangibles | $4.55B | $4.55B | $4.58B | $4.76B | $4.74B | $4.94B | $4.66B | $4.50B |
| Total assets | $7.48B | $7.61B | $7.98B | $8.54B | $10.08B | $10.09B | $9.76B | $9.65B |
| Current liabilities | $1.02B | $1.05B | $997.60M | $1.01B | $1.15B | $1.13B | $1.07B | $1.04B |
| Short-term debt | $11.30M | $11.40M | $11.40M | $36.60M | $36.60M | $36.40M | $36.20M | $36.40M |
| Long-term debt | $3.28B | $3.28B | $3.62B | $3.60B | $3.61B | $3.62B | $3.59B | $3.58B |
| Total debt | $3.29B | $3.29B | $3.63B | $3.64B | $3.64B | $3.65B | $3.63B | $3.62B |
| Total liabilities | $5.04B | $5.09B | $5.48B | $5.60B | $5.64B | $5.62B | $5.40B | $5.33B |
| Shareholders' equity | $2.44B | $2.52B | $2.50B | $2.94B | $4.45B | $4.47B | $4.36B | $4.32B |
| Net debt | $2.86B | $2.90B | $3.28B | $3.11B | $3.21B | $3.20B | $3.22B | $3.06B |
| Shares outstanding | 138.80M | 138.70M | 138.10M | 137.60M | 137.60M | 137.60M | 137.20M | 136.50M |
| Cash flow statement | ||||||||
| Operating cash flow | $96.20M | $82.60M | -$113.60M | $175.40M | $51.70M | $75.90M | -$64.50M | $312.60M |
| Capital expenditure | $17.50M | $14.30M | $13.80M | $26.80M | $21.90M | $19.20M | $25.50M | $37.70M |
| Free cash flow | $78.70M | $68.30M | -$127.40M | $148.60M | $29.80M | $56.70M | -$90.00M | $274.90M |
| Investing cash flow | -$13.60M | $349.40M | -$12.40M | -$24.50M | -$21.40M | -$3.80M | -$25.70M | -$37.10M |
| Financing cash flow | -$43.50M | -$388.90M | -$45.30M | -$54.40M | -$50.30M | -$54.00M | -$61.80M | -$1.15B |
| Depreciation & amortization | $27.50M | $41.40M | $83.30M | $85.90M | $29.40M | $29.30M | $79.90M | $80.30M |
| Stock-based compensation | $10.10M | $6.80M | $14.40M | $13.00M | $13.20M | $16.80M | $11.60M | $19.90M |
| Dividends paid | $40.20M | $40.20M | $39.90M | $39.90M | $39.90M | $38.90M | $40.60M | $39.60M |
Free plan shows the latest 8 periods; Pro shows all 60 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.